ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have received a consensus rating of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $103.4286.

ANIP has been the subject of a number of recent analyst reports. Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price for the company. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th.

Key ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Management will present at three major investor conferences in early March (Raymond James, Leerink Partners, Barclays); live and archived webcasts available on the company site for 90 days — helps visibility and investor access to management’s growth story. GlobeNewswire Release
• Positive Sentiment: Analyst coverage remains constructive: recent buy/overweight ratings and several price targets well above the current price (median/consensus targets indicate upside), supporting investor confidence. MarketBeat Analyst Notes
• Neutral Sentiment: Street preview pieces highlight expected strength in Cortrophin Gel and rare-disease momentum ahead of Q4 results — this implies potential upside but also flags generic pressure risks; outcome depends on reported numbers. Zacks Preview
• Neutral Sentiment: Recorded short-interest data in the feed shows zero shares / anomalous NaN change and a 0.0 days-to-cover metric — appears to be a data glitch and is unlikely to be an actionable signal by itself.
• Neutral Sentiment: Institutional/hedge-fund activity is mixed: some large reallocations reported (both adds and sizable removals across different funds in the latest quarter), so ownership trends are shifting but not uniformly bullish or bearish. Quiver Quant Summary
• Negative Sentiment: Several insiders (including SVP Krista Davis and Head of Rare Disease Christopher Mutz) disclosed market sales of ANIP shares in recent sessions; repeated insider selling can be perceived as a modest negative signal for near-term sentiment. InsiderTrades Filing

Insider Transactions at ANI Pharmaceuticals

In related news, insider Christopher Mutz sold 5,323 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $78.02, for a total transaction of $415,300.46. Following the sale, the insider directly owned 84,840 shares of the company’s stock, valued at $6,619,216.80. This represents a 5.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Renee P. Tannenbaum sold 1,800 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $81.15, for a total transaction of $146,070.00. Following the sale, the director owned 25,157 shares in the company, valued at approximately $2,041,490.55. This trade represents a 6.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 13,459 shares of company stock valued at $1,066,611. Insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of large investors have recently modified their holdings of ANIP. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals in the first quarter valued at $28,000. Hantz Financial Services Inc. raised its position in ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares in the last quarter. Newbridge Financial Services Group Inc. boosted its stake in shares of ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 400 shares during the period. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter worth about $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth approximately $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $76.70 on Wednesday. The stock has a fifty day simple moving average of $80.60 and a 200-day simple moving average of $86.60. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The stock has a market cap of $1.72 billion, a PE ratio of 47.06 and a beta of 0.50. ANI Pharmaceuticals has a twelve month low of $54.10 and a twelve month high of $99.50.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.